SCHEMBL710187

SCHEMBL710187

Nc1nnc(Cl)cc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29910731 1.00
SCHEMBL10692642 0.74
SCHEMBL30121690 0.74
SCHEMBL1576635 0.74
SCHEMBL30930706 0.74
SCHEMBL25214392 0.74
SCHEMBL2936869 0.74
SCHEMBL2646498 0.74
SCHEMBL30812605 0.74
SCHEMBL18038723 0.72 CHRNB2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005615-A Pyridazine compound and preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-05-10 CN claimed
CN-116082110-B The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof 北京肿瘤医院(北京大学肿瘤医院) 2024-04-12 CN claimed
CN-117756729-A Preparation method of deuterium-celecoxib and intermediate thereof 上海鼎雅药物化学科技有限公司 2024-03-26 CN claimed
CN-116082110-A The method comprises the following steps of 11 C-labeled targeted anaplastic lymphoma kinase ALK mutant molecular probe and application thereof 北京肿瘤医院(北京大学肿瘤医院) 2023-05-09 CN claimed
CN-104402828-A Synthetic method of 3-amino-4-bromo-6-chlorodiazine DINGTAO COUNTY YOUBANG CHEMICAL INDUSTRY CO LTD 2015-03-11 CN claimed
WO-2026107406-A1 p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF Design Therapeutics, Inc. (US) 2026-05-21 WO disclosed
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
WO-2026098598-A1 COMPOUND CONTAINING THREE FUSED HETEROCYCLIC RINGS 正大天晴药业集团股份有限公司 2026-05-15 WO disclosed
CN-122036699-A THR-beta modulators and methods of use thereof 阿利戈斯治疗公司 2026-05-15 CN disclosed
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 US disclosed
EP-4727541-A2 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Plexium, Inc. (US) 2026-04-22 EP disclosed
EP-4727543-A2 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Plexium, Inc. (US) 2026-04-22 EP disclosed
WO-2007013673-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-02-01 WO disclosed
US-20060211696-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-09-21 US disclosed
US-20060189613-A1 Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) ASTRAZENECA AB (SE) 2006-08-24 US disclosed
US-7078405-B2 Imidazo[1,2-b]pyridazine compound EISAI CO., LTD. (JP) 2006-07-18 US disclosed
EP-1633723-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) AstraZeneca AB (SE) 2006-03-15 EP disclosed
WO-2004108690-A1 SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) ASTRAZENECA AB (SE) 2004-12-16 WO disclosed
US-20040082781-A1 Bicyclic nitrogenous fused-ring compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-04-29 US disclosed
EP-1364952-A1 BICYCLIC NITROGENOUS FUSED-RING COMPOUND Eisai Co., Ltd. (JP) 2003-11-26 EP disclosed